Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AR signaling inhibitors (ARSi).

被引：0
|
作者：
Schonhoft, Joseph
Gill, Audrey
Graf, Ryon P.
Jendrisak, Adam
Barnett, Ethan
Benoliel, Hannah
Carbone, Emily
Tubbs, Alisa
Orr, Sarah
Byun, Jiyun
Wenstrup, Rick
Scher, Howard, I
机构：
[1] Epic Sci Inc, San Diego, CA USA
[2] Epic Sci, San Diego, CA USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5571
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC).
    Bitting, Rhonda Lynn
    Healy, Patrick
    Halabi, Susan
    George, Daniel J.
    Ko, Jung Hyun
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer (mCRPC).
    Conteduca, Vincenza
    Castro, Elena
    Jayaram, Anuradha
    Wetterskog, Daniel
    Scarpi, Emanuela
    Romero-Laorden, Nuria
    Olmos, David
    Gurioli, Giorgia
    Lolli, Cristian
    Puente, Javier
    Medina, Ana
    Querol, Rosa
    Angel Arranz, Jose
    Isabel Saez, Maria
    Fornarini, Giuseppe
    Basso, Umberto
    Mellado, Begona
    Gonzalez-Billalabeitia, Enrique
    Attard, Gerhardt
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Comparison of the Epic CTC HRD assay vs. tumor DDR mutations in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)
    Schonhoft, Joseph
    Jendrisak, Adam
    Lee, Jerry
    Rodriguez, Angel
    Sutton, Ramsay
    Wang, Yipeng
    Dittamore, Ryan
    Landers, Mark
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
    Tucker, Matthew D.
    Zhu, Jason
    Berry, William R.
    Ramalingam, Sundhar
    Zhang, Tian
    Harrison, Michael Roger
    Wu, Yuan
    Healy, Patrick
    George, Daniel J.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
    Tralongo, P.
    Bordonaro, S.
    Di Lorenzo, G.
    Borsellino, N.
    Facchini, G.
    Rossetti, S.
    Martelli, V.
    Longo, V.
    Tralongo, A. C.
    Caspani, F.
    Tuzi, A.
    Spada, M.
    Calvani, N.
    Carlini, P.
    De Giorgi, U. F. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY.
    Tagawa, Scott T.
    Galletti, Giuseppe
    Antonarakis, Emmanuel S.
    Tasaki, Shinsuke
    Gjyrezi, Ada
    Worroll, Daniel
    Portella, Luigi
    Kirby, Brian J.
    Stewart, John
    Zaher, Atef
    Saad, Fred
    Vanhuyse, Marie
    Suri, Shalu
    Lannin, Timothy B.
    Gruber, Conor
    Pratt, Erica
    Sonpavde, Guru
    Eisenberger, Mario A.
    Nanus, David M.
    Giannakakou, Paraskevi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Circulating tumor cell (CTC) enumeration in patients with metastatic neuroendocrine prostate cancer (NEPC) and castration-resistant prostate cancer (CRPC)
    Kaur, Gurveen
    Singh, Beerinder
    Beltran, Himisha
    Akhtar, Naveed Hassan
    Nanus, David M.
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [8] Study on Pradiction of AR-V7 and CTC Circulation in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Rexer, H.
    Hammerer, P.
    Schostak, M.
    Koenig, F.
    AKTUELLE UROLOGIE, 2018, 49 (05) : 392 - 393
  • [9] Sequential monitoring and characterization of circulating tumor cells (CTCs) using the epic sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics.
    Ferraldeschi, Roberta
    Krupa, Rachel
    Louw, Jessica
    Tucker, Eric
    Bales, Natalee
    Marrinucci, Dena
    Flohr, Penelope
    Figueiredo, Ines
    Lorente, David
    Dittamore, Ryan
    De Bono, Johann Sebastian
    Attard, Gerhardt
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [10] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
12345